Skip to main content
Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The Case for BTKi
Published Web Location
https://doi.org/10.1182/bloodadvances.2019001204Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.